Coya Therapeutics (COYA) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing therapies to enhance regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases.

• Lead asset COYA 302 is a Treg-enhancing biologic, combining low dose interleukin-2 and CTLA4-Ig, targeting neurodegenerative disorders such as ALS.

• Pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, with both ex vivo and in vivo approaches.

• Ongoing ALSTARS Phase 2 trial for COYA 302 in ALS; product not yet FDA approved.

Financial performance and metrics

• Net losses of $21.2 million in 2025 and $14.9 million in 2024; accumulated deficit of $62.0 million as of December 31, 2025.

• Operations funded primarily through private and public securities sales.

• Received $7.5 million upfront from Dr. Reddy's in January 2024, with additional milestone and royalty payments possible.

Use of proceeds and capital allocation

• No proceeds from this offering will go to the company; all shares are being resold by selling stockholders.

• Company will pay registration-related legal and accounting fees.